Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 121

Results For "patients"

4124 News Found

Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim
Supply Chain | July 18, 2025

Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim

Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes


Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant
Clinical Trials | July 17, 2025

Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant

There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated


Corona Remedies acquires 7 brands from Bayer's pharma division in India
News | July 17, 2025

Corona Remedies acquires 7 brands from Bayer's pharma division in India

This marks the fourth acquisition by Corona Remedies from multinational corporations


Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey
News | July 17, 2025

Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey

Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers


Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL
Drug Approval | July 15, 2025

Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL

Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments


Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
News | July 15, 2025

Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy

Capricor’s BLA for Deramiocel received Priority Review in March 2025


Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata
News | July 14, 2025

Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata

LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients


AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Clinical Trials | July 14, 2025

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo